ARA 290 (cibinetide) is an erythropoietin-derived research peptide studied in three cited clinical investigations of neuropathic symptoms and related endpoints. Those papers concern defined investigational material used under specific protocols; they do not validate an independently supplied wholesale batch. The current price list contains five Injectable entries labelled 5, 10, 12, 16 and 20, but it does not state the dosage unit. Confirm the exact peptide identity, terminal form, fill amount, counterion and batch methods before ordering.
| Class | ARA 290 (cibinetide), an erythropoietin-derived research peptide. |
| Identity boundary | The cited PNAS paper describes HBSP and pHBSP constructs, but it does not identify either construct as ARA 290 or cibinetide. Confirm the exact quoted peptide identity and terminal form from product and batch documents. |
| Identity reference | PubChem identifies cibinetide as compound CID 91810664; reconcile the quoted name, molecular form and counterion with batch identity evidence. |
| Listed presentations | 5, 10, 12, 16 and 20 / Injectable. The price list does not state the dosage unit or fill composition. |
| Batch qualification | Verify peptide identity, chromatographic area purity, net peptide content, related substances, water and residual solvents in current lot documents. |
| Handling | Use the formulation, shipping condition, storage range, diluent and in-use window issued for the allocated batch. |
Wholesale from $4.08
Published wholesale tiers apply when the order reaches 100+ total units; the tier is selected by quantity of each SKU. Smaller total orders are quoted separately.
| SKU / form | 10–24 units of this SKU | 25–49 units of this SKU | 50+ units of this SKU |
|---|---|---|---|
| 10 / Injectable | $8.16 | $7.14 | $6.12 |
| 12 / Injectable | $9.52 | $8.33 | $7.14 |
| 16 / Injectable | $12.24 | $10.71 | $9.18 |
| 20 / Injectable | $13.60 | $11.90 | $10.20 |
| 5 / Injectable | $5.44 | $4.76 | $4.08 |
The catalogue name and an HPLC percentage are not enough to establish ARA-290 identity or usable peptide content. Resolve the exact molecular form and lot documentation before comparing quotes.
Confirm the exact quoted peptide identity, N- and C-terminal forms, counterion and batch LC-MS identity result. Do not assign the HBSP or pHBSP construct from the PNAS paper to ARA 290 or cibinetide without separate identity evidence.
Review the HPLC method and chromatogram together with net peptide content, related substances, water and residual-solvent results. Area purity is not the peptide mass per vial.
Confirm the dosage unit, fill amount, excipients, endotoxin or bioburden requirement, shipping condition and supported handling window for the intended protocol.
The three cited clinical papers evaluated defined investigational ARA 290 under study protocols. They do not prove equivalence, stability, safety or performance for a separate supplier lot.
Brines et al. (2008). Nonerythropoietic, tissue-protective peptides derived from the tertiary structure of erythropoietin. Proceedings of the National Academy of Sciences. DOI: 10.1073/pnas.0805594105
Study scope: Cell and animal systems used to define nonerythropoietic tissue-protective erythropoietin-derived peptides. HBSP and its N-terminally cyclized pHBSP form as defined in the paper; the paper does not identify either construct as ARA 290 or cibinetide.
What it supports: Supports only background on HBSP and pHBSP peptide design from erythropoietin-derived structure; it does not establish ARA 290 or cibinetide identity.
Boundary: Do not use this paper to assign an exact sequence or terminal form to ARA 290 or cibinetide. It also does not establish human efficacy, an approved indication, or the identity and quality of an independently supplied batch.
Heij et al. (2012). Safety and Efficacy of ARA 290 in Sarcoidosis Patients with Symptoms of Small Fiber Neuropathy: A Randomized, Double-Blind Pilot Study. Molecular Medicine. DOI: 10.2119/molmed.2012.00332
Study scope: Patients with sarcoidosis and symptoms of small-fiber neuropathy in a small pilot study. Defined investigational ARA 290 administered under the paper's protocol.
What it supports: Supports describing the safety and symptom observations reported for that specific pilot population and protocol.
Boundary: A small pilot does not establish general efficacy, regulatory approval, a universal dose, or equivalence with a wholesale batch.
Dahan et al. (2013). ARA 290 Improves Symptoms in Patients with Sarcoidosis-Associated Small Nerve Fiber Loss and Increases Corneal Nerve Fiber Density. Molecular Medicine. DOI: 10.2119/molmed.2013.00122
Study scope: Patients with sarcoidosis-associated small nerve-fiber loss assessed for symptoms and corneal nerve-fiber density. Defined investigational ARA 290 used under the study protocol; the source record indexes ARA 290 with cibinetide.
What it supports: Supports a narrow account of the reported symptom and corneal nerve-fiber-density findings in that population.
Boundary: The study does not validate a commercial lot, establish broad neuropathy efficacy, or supply a general handling specification.
Brines et al. (2015). ARA 290, a Nonerythropoietic Peptide Engineered from Erythropoietin, Improves Metabolic Control and Neuropathic Symptoms in Patients with Type 2 Diabetes. Molecular Medicine. DOI: 10.2119/molmed.2014.00215
Study scope: Patients with type 2 diabetes assessed for protocol-defined metabolic and neuropathic-symptom endpoints. Defined investigational ARA 290 administered within the reported clinical protocol; the source record indexes ARA 290 with cibinetide.
What it supports: Supports stating that metabolic-control and neuropathic-symptom outcomes were studied in that defined clinical setting.
Boundary: It does not establish a treatment indication, general safety or efficacy, or supplier-batch equivalence.
ARA 290 (cibinetide) is an erythropoietin-derived research peptide. The cited clinical papers evaluated defined investigational ARA 290, and this page does not present it as an approved treatment or use the HBSP/pHBSP paper to assign an exact sequence.
The cited papers describe ARA 290 as a nonerythropoietic peptide derived from erythropoietin. That design description does not make a supplier batch interchangeable with erythropoietin or prove a clinical outcome.
No. They evaluated defined investigational material under specific protocols. A separate lot still requires identity, content, impurity and handling documentation.
The current price list contains 5, 10, 12, 16 and 20 / Injectable entries. The dosage unit and fill composition are not stated and must be confirmed in the quote.
The five ARA-290 entries have separate 10+, 25+ and 50+ per-SKU tiers. Published tiers apply when the order reaches 100+ total units; smaller total orders are quoted separately.
Use the instructions for the allocated batch and formulation. This page does not assert one universal storage temperature, diluent or post-reconstitution window.